Please select the eligibility criteria that correspond to the clinical trial below.
Title: Effects of MBSR in Early Stage Breast Cancer Recovery
Brief Summary: The purpose of this study was two-fold: (i) to assess whether MBSR favorably influences psychological status, quality of life, stress hormones, and immune status in breast cancer survivors; and (ii) to explore possible mechanisms by which MBSR may favorably influence these outcomes, in particular, through reduction in fear of breast cancer recurrence and associated perceived stress. Both objectives were studied at the critical transition time immediately following completion of surgical, radiation and/or chemotherapy therapy for breast cancer.


Options:
A: DISEASE CHARACTERISTICS:

* Previously diagnosed with primary breast cancer
* Must have received 4½ - 6 years of aromatase inhibitor therapy (e.g., letrozole, anastrozole, or exemestane), either as initial therapy or after prior tamoxifen citrate, including treatment received as part of clinical trial CAN-NCIC-MA17

  * Completed aromatase inhibitor therapy ≤ 2 years ago
* No metastatic or recurrent disease, contralateral breast cancer, or ductal carcinoma in situ in either breast, as determined by the following:

  * Clinical examination of the breast area, axillae, and neck within the past 60 days
  * Mammogram within the past 12 months\*
  * Chest x-ray within the past 60 days
  * Bone scan, if alkaline phosphatase \> 2 times normal and/or there are symptoms of metastatic disease AND confirmatory x-ray, if bone scan results are questionable, within the past 60 days
  * Abdominal ultrasound, liver scan, or CT scan of the abdomen within the past 60 days, if ALT, AST, or alkaline phosphatase \> 2 times normal NOTE: \*A baseline mammogram is not required for patients who have undergone bilateral complete mastectomy
* Hormone-receptor status:

  * Estrogen receptor positive (ER+) and/or progesterone receptor positive (PR+) primary tumor at the time of diagnosis, defined as a tumor receptor content of \> 10 fmol/mg protein or receptor positive by immunocytochemical assay (for patients not previously enrolled on clinical trial CAN-NCIC-MA17)
  * ER+ and/or PR+ primary tumor OR hormone receptor status of primary tumor unknown (for patients previously enrolled on clinical trial CAN-NCIC-MA17)

PATIENT CHARACTERISTICS:

* Menopausal status not specified
* ECOG performance status 0-2
* Life expectancy ≥ 5 years
* WBC \> 3.0 x 10\^9/L OR granulocyte count (polymorphs + bands) ≥ 1.5 times 10\^9/L
* Platelet count \> 100 x 10\^9/L
* AST and/or ALT \< 2 times upper limit of normal (ULN)\*
* Alkaline phosphatase \< 2 times ULN\*
* Able (i.e. sufficiently fluent) and willing to complete quality-of-life questionnaires in either English or French (NCIC CTG participating centers)

  * Inability to complete questionnaires due to illiteracy in English or French, loss of sight, or other equivalent reason allowed
* Accessible for treatment and follow-up
* No other prior or concurrent malignancy except adequately treated, superficial squamous cell or basal cell skin cancer, carcinoma in situ of the cervix, or other cancer treated \> 5 years ago that is presumed cured NOTE: \*Elevated levels allowed provided imaging examinations have ruled out metastatic disease

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* No concurrent selective estrogen receptor modulator (e.g., raloxifene, idoxifene)
* No other concurrent anticancer therapy
B: Inclusion Criteria:

* 21 years or older
* Diagnosed with Stage 0, I, II, or III breast cancer
* Undergone lumpectomy and/or mastectomy and are at 2 weeks from end of treatment with adjuvant radiation and/or chemotherapy or are a maximum of 2 years out from completion of such treatment
* Ability to read and speak English at the 8th grade level or above to respond to survey questions

Exclusion Criteria:

* Advanced stage (IV) cancer
* Current psychiatric diagnosis
* Recurrent treatment for prior breast cancer
C: Inclusion Criteria:

* patients diagnosed with breast cancer after completion of adjuvant chemotherapy or radiation therapy, with/or without endocrine therapy

Exclusion Criteria:

* patients with advanced illness at diagnosis
* patients previously used MBSR
D: Inclusion Criteria:

* 21 years old or older
* Diagnosed with Stage 0, I, II, or III breast cancer
* Undergone lumpectomy and completed adjuvant radiation and/or chemotherapy (end of treatment to 18 months post-treatment)
* Ability to read and speak English at the 8th grade level to respond to the survey questions

Exclusion Criteria:

* Advanced stage (IV) breast cancer
* History of mastectomy
* Current psychiatric diagnosis
* Recurrent treatment for prior breast cancer

Answer: D